Helen X. Chen, M.D.
Associate Branch Chief, Immunooncology
Investigational Drug Branch
NCI Division of Cancer Treatment and Diagnosis (DCTD) Cancer Therapy Evaluation Program (CTEP)
Dr. Helen Chen joined NCI’s Cancer Therapy Evaluation Program (CTEP) in 2000. She currently serves as Associate Chief of Immuno-oncology for the Investigational Drug Branch (IDB), leading activities related to the clinical development of new cancer immunotherapy agents and therapeutic antibodies. Dr. Chen is board-certified in Medical Oncology after completing her Fellowship training at Georgetown University Medical Center in Washington D.C.